Julie L. Gerberding - 24 Feb 2022 Form 4 Insider Report for Merck & Co., Inc. (MRK)

Reporting relationship: EVP, Chief Patient Officer
Issuer ticker: MRK
Reported as of: 24 Feb 2022
Net transaction value: +$702,020
SEC form: 4
Accepted by SEC: 28 Feb 2022, 15:17:42 UTC
Prior SEC filing: 03 Nov 2021
Next SEC filing: 28 Apr 2022
Source filing: View source filing
Reporting owner signature: /s/ Kelly E. W. Grez as Attorney-in-Fact for Julie L. Gerberding

Key filing fact

Julie L. Gerberding filed Form 4 for Merck & Co., Inc. (MRK) on 28 Feb 2022.

Key facts

This page summarizes Julie L. Gerberding's Form 4 filing for Merck & Co., Inc. (MRK).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 28 Feb 2022, 15:17.

Change

Previous filing in this sequence was filed on 03 Nov 2021.
Current net transaction value: +$702,020.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MRK transaction

Common Stock

Award

Transaction value: $702,020
Shares: +9,550
Change %: +24%
Price: $73.51
Shares after: 48,712
Date: 24 Feb 2022
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/29/19. Performance shares were paid out at 140 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2021.

Footnote F2

Holdings include shares acquired in dividend reinvestment transactions.